Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) – Stock analysts at Wedbush issued their Q1 2022 earnings per share (EPS) estimates for shares of Alpine Immune Sciences in a research note issued to investors on Monday, March 21st. Wedbush analyst R. Driscoll anticipates that the biotechnology company will earn ($0.27) per share for the […]
Zacks Investment Research cut shares of Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) from a hold rating to a sell rating in a report issued on Tuesday morning, Zacks.com reports. According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the […]
Wall Street brokerages expect Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) to post ($0.08) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have issued estimates for Alpine Immune Sciences’ earnings. Alpine Immune Sciences posted earnings per share of ($0.45) in the same quarter last year, which would indicate a positive […]
Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.23), MarketWatch Earnings reports. Alpine Immune Sciences had a negative return on equity of 58.85% and a negative net margin of 169.03%. Shares […]